Mozart Therapeutics
Fabio Pucci has been an investor at Leaps by Bayer, the investment arm of the global life sciences company Bayer, since 2021. He is responsible for search and evaluation, as well as healthcare focused investment across a wide spectrum of therapeutic modalities and indications. Fabio currently serves as board director or observer for Capstan, Immunitas, Indapta, Kojin, and, previously, for Hemab. Prior to Leaps by Bayer, Fabio worked at RA Capital, a biotech multistage investment fund, and worked at the Francis Crick Institute in London as a cancer researcher. Fabio obtained his PhD from the Wellcome Trust Centre for Cell Biology and his MBA from the London Business School.
This person is not in the org chart
This person is not in any offices
Mozart Therapeutics
Mozart Therapeutics is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is using a novel regulatory CD8 T cell network to create disease-modifying CD8 Treg modulators for a variety of autoimmune diseases. Mozart is developing a pipeline of first-in-class 'CD8Treg modulators with the goal of restoring long-term immune balance and preventing the progressive damage caused by an autoreactive and pathogenic immune response.